Sandoz announced the launch of generic oncology medicine lenalidomide, indicated for several haemato-oncology conditions as recommended by the latest European Society for Medical Oncology (ESMO) guidelines. The medicine will become available to patients in 19 countries across Europe.

“We are proud to make life-enhancing cancer treatments more accessible by launching our affordable and effective Sandoz lenalidomide”, said Rebecca Guntern, Head of Sandoz Europe.

She added: “Sandoz is committed to developing and providing generic oncology therapies, to increase patient access to affordable, high-quality medicines. Today, we offer a broad portfolio of more than 50 oncology products, ranging from biologics to chemotherapeutics, hormones and supportive care treatments, covering a wide range of cancer indications."

The cost of treating multiple myeloma patients is high and continues to rise. Affordability of and access to new multiple myeloma treatments pose a major challenge around the world. Cost savings from lenalidomide Sandoz promise to expand access to treatment options for multiple myeloma patients.

Sandoz is one of the leading supplier of generic oncology medicines in Europe with a growing portfolio that covers an industry-leading 75% of molecules on the WHO's global Oncology Essential Medicines List. Sandoz invests in development to improve the lives of cancer patients and free up healthcare resources through increased access to high-quality, affordable medicines.